Track topics on Twitter Track topics that are important to you
(MedPage Today) -- Pirfenidone and nintedanib get conditional recommendation.
(MedPage Today) -- Patients with idiopathic pulmonary fibrosis who have an early decline in FVC while on pirfenidone should stay on treatment.
Experts say the launch of Boehringer Ingelheim’s new treatment for idiopathic pulmonary fibrosis (IPF) offers stiff competition to Roche’s Esbriet that serve to ultimately benefit patients. Boehri...
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is pursuant to a ...
The prospects for patients in Europe with the rare debilitating and fatal lung disease idiopathic pulmonary fibrosis are looking up with the imminent market arrival of Boehringer Ingelheim's Ofev.Ofev...
MORRISTOWN, N.J., July 6, 2015 /PRNewswire/ -- Moerae Matrix, a clinical stage biotechnology company focused on developing novel therapeutics that target inflammation and fibrosis, today announced the...
Roche's rheumatoid arthritis (RA) drug Actemra/RoActemra could be an important therapy for the life-threatening autoimmune disease systemic sclerosis (SSc), according to the US FDA.The US regulator ha...
Recently added to the BioPortfolio report store, Physician Views: Idiopathic pulmonary fibrosis – on the cusp of a revolution; how will forthcoming approvals shape the treatment and development lan...
Pirfenidone (esbiret) is an established anti‑fibrotic and anti‑inflammatory drug used to treat idiopathic pulmonary fibrosis. In the present study, the dose‑dependent effects of pirfenidone on t...
A rapid, sensitive and selective ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) was developed and validated for the determination and pharmacokinetic investigation of pi...
treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical cl...
Forced vital capacity (FVC) outcomes in clinical trials in idiopathic pulmonary fibrosis (IPF) can be substantially influenced by the analytic methodology and the handling of missing data. We conducte...